PPARG and polycystic ovary syndrome: This is evident further from intervention trials improving insulin resistance in PCOS women using different therapies e.g., weight loss, metformin, D-chiro-inositol and peroxisome proliferator-activated receptor gamma (PPARɤ)-agonists demonstrating reduced androgen levels with improved exaggerated androgenic response to ACTH, or LH stimulation tests (22–24).